All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

IMA203 Demonstrates Early Promise in PD-1–Refractory Metastatic Melanoma

June 5th 2025

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

June 5th 2025

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy

June 4th 2025

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Understanding Your Risk: Are Women Likelier to Have Thyroid Cancer Than Men Are?

June 4th 2025

Recent research at Mayo Clinic evaluated thyroid cancer risk in men and women.

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma

June 4th 2025

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.

Multidisciplinary Collaboration Is Essential in Early-Stage NSCLC

June 4th 2025

In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.

Annamycin Drives Clinical Benefit in Soft Tissue Sarcoma Lung Metastases

June 4th 2025

Annamycin yielded a 59.4% CBR and a median OS of 13.5 months in soft tissue sarcoma lung metastases.

Iopofosine I 131 Earns FDA Breakthrough Designation for R/R Waldenström Macroglobulinemia

June 4th 2025

The FDA granted breakthrough therapy designation to iopofosine I 131 for relapsed/refractory Waldenström macroglobulinemia.

Accelerated FDA Approval Establishes Role of Avutometinib/Defactinib in KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer

June 4th 2025

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma

June 4th 2025

Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

June 3rd 2025

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma

June 3rd 2025

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.

Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma

June 3rd 2025

Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.